文献速递间质性肺疾病

家族性间质性肺炎高危人群中纤维化肺病的发病率与进展

Incidence and Progression of Fibrotic Lung Disease in an At-Risk Cohort.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

本研究对家族性间质性肺炎(FIP)患者的一级亲属进行队列研究,基线及约4年后重复高分辨率CT评估。无症状一级亲属493例基线评估,296例参与后续评估。PrePF年发病率保守估计为1023/10万人年(95%CI 511-1831),基线PrePF与生存期缩短相关。

要点

  • FIP患者一级亲属中临床前肺纤维化(PrePF)年发病率至少为散发性IPF的100倍。
  • 基线存在PrePF者4年后呼吸困难加重比例显著高于无PrePF者(38.4% vs 15.4%,P=0.002)。
  • 基线PrePF与生存期缩短显著相关(P<0.001),提示其呈进展性。

核心结论

  • PrePF在FIP患者一级亲属中的发病率至少为散发性IPF的100倍。
  • PrePF与IPF虽为不同实体,但PrePF同样呈进展性且与生存期缩短相关。

研究设计与样本

  • 队列研究,纳入FIP患者的一级亲属,基线及约4年后重复健康问卷和高分辨率CT评估。
  • 493例无症状一级亲属完成基线评估,296例(60%)参与后续评估。

主要发现

  • 两次HRCT中位间隔3.9年(四分位距3.5-4.4年)。
  • 基线无PrePF且同意重复评估的252例中,16例新发PrePF。
  • PrePF年发病率保守估计为1023/10万人年(95%CI 511-1831/10万人年)。
  • 基线PrePF者呼吸困难加重比例38.4%,无PrePF者15.4%(P=0.002)。
  • HRCT显示普通型间质性肺炎(P<0.0002)和基线定量纤维化评分(P<0.001)与呼吸困难加重相关。

临床怎么用

  • 对FIP患者一级亲属应进行HRCT筛查以识别PrePF。
  • 发现PrePF后需密切随访,因其进展风险高且与生存期缩短相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Relatives of patients with familial interstitial pneumonia (FIP) are at increased risk for pulmonary fibrosis and develop preclinical pulmonary fibrosis (PrePF). Objectives: We defined the incidence and progression of new-onset PrePF and its relationship to survival among first-degree relatives of families with FIP. Methods: This is a cohort study of family members with FIP who were initially screened with a health questionnaire and chest high-resolution computed tomography (HRCT) scan, and approximately 4 years later, the evaluation was repeated. A total of 493 asymptomatic first-degree relatives of patients with FIP were evaluated at baseline, and 296 (60%) of the original subjects participated in the subsequent evaluation. Measurements and Main Results: The median interval between HRCTs was 3.9 years (interquartile range, 3.5-4.4 yr). A total of 252 subjects who agreed to repeat evaluation were originally determined not to have PrePF at baseline; 16 developed PrePF. A conservative estimate of the annual incidence of PrePF is 1,023 per 100,000 person-years (95% confidence interval, 511-1,831 per 100,000 person-years). Of 44 subjects with PrePF at baseline, 38.4% subjects had worsening dyspnea compared with 15.4% of those without PrePF (P = 0.002). Usual interstitial pneumonia by HRCT (P < 0.0002) and baseline quantitative fibrosis score (P < 0.001) are also associated with worsening dyspnea. PrePF at the initial screen is associated with decreased survival (P < 0.001). Conclusions: The incidence of PrePF in this at-risk population is at least 100-fold higher than that reported for sporadic idiopathic pulmonary fibrosis (IPF). Although PrePF and IPF represent distinct entities, our study demonstrates that PrePF, like IPF, is progressive and associated with decreased survival.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Steele MP, Peljto AL, Mathai SK, et al. Incidence and Progression of Fibrotic Lung Disease in an At-Risk Cohort. Am J Respir Crit Care Med. 2023. PMID: 36094461. doi:10.1164/rccm.202206-1075OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。